- Home
- ECOR vs CMRX Comparison
ECOR vs CMRX Comparison
Compare ECOR & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- CMRX
- Stock Information
- Founded
- ECOR 2005
- CMRX 2000
- Country
- ECOR United States
- CMRX United States
- Employees
- ECOR N/A
- CMRX N/A
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- ECOR Health Care
- CMRX Health Care
- Exchange
- ECOR Nasdaq
- CMRX Nasdaq
- Market Cap
- ECOR 65.0M
- CMRX 77.1M
- IPO Year
- ECOR 2018
- CMRX 2013
- Fundamental
- Price
- ECOR $16.49
- CMRX $2.79
- Analyst Decision
- ECOR Strong Buy
- CMRX Strong Buy
- Analyst Count
- ECOR 1
- CMRX 2
- Target Price
- ECOR $15.00
- CMRX $8.50
- AVG Volume (30 Days)
- ECOR 97.7K
- CMRX 11.2M
- Earning Date
- ECOR 11-13-2024
- CMRX 11-07-2024
- Dividend Yield
- ECOR N/A
- CMRX N/A
- EPS Growth
- ECOR N/A
- CMRX N/A
- EPS
- ECOR N/A
- CMRX N/A
- Revenue
- ECOR $23,327,000.00
- CMRX $159,000.00
- Revenue This Year
- ECOR $61.40
- CMRX N/A
- Revenue Next Year
- ECOR $38.43
- CMRX $1,690.28
- P/E Ratio
- ECOR N/A
- CMRX N/A
- Revenue Growth
- ECOR 74.10
- CMRX N/A
- 52 Week Low
- ECOR $5.25
- CMRX $0.75
- 52 Week High
- ECOR $15.25
- CMRX $3.39
- Technical
- Relative Strength Index (RSI)
- ECOR 69.93
- CMRX 84.35
- Support Level
- ECOR $13.22
- CMRX $2.74
- Resistance Level
- ECOR $14.87
- CMRX $3.02
- Average True Range (ATR)
- ECOR 1.34
- CMRX 0.26
- MACD
- ECOR 0.30
- CMRX 0.18
- Stochastic Oscillator
- ECOR 87.04
- CMRX 77.13
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.